Total Revenue
Edwards Lifesciences Total Revenue increased by 5.0% to $1.65B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.7%, from $1.41B to $1.65B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 3.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.38B | $1.31B | $1.33B | $1.34B | $1.37B | $1.32B | $1.35B | $1.46B | $1.53B | $1.48B | $1.27B | $1.33B | $1.37B | $1.35B | $1.39B | $1.41B | $1.53B | $1.55B | $1.57B | $1.65B |
| QoQ Change | — | -4.8% | +1.5% | +0.9% | +2.4% | -4.0% | +2.2% | +8.3% | +4.8% | -3.2% | -14.5% | +5.0% | +3.0% | -1.1% | +2.3% | +1.9% | +8.5% | +1.4% | +1.1% | +5.0% |
| YoY Change | — | — | — | — | -0.2% | +0.7% | +1.4% | +8.8% | +11.4% | +12.3% | -6.1% | -8.9% | -10.5% | -8.5% | +9.4% | +6.2% | +11.9% | +14.7% | +13.3% | +16.7% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $1.04B | $1.02B | $1.04B | $1.05B | $1.13B | $1.15B | $1.16B | $1.20B |
| Surgical | — | — | — | — | — | — | — | $276.20M |
| Transcatheter Mitral and Tricuspid Therapies | $83.00M | $91.10M | $105.10M | $115.20M | $134.50M | $145.20M | $155.70M | $175.10M |
| Surgical Structural Heart | $264.30M | $240.00M | $210.90M | $250.90M | $266.80M | $258.00M | $253.60M | — |
| Total | $1.37B | $1.35B | $1.39B | $1.41B | $1.53B | $1.55B | $1.57B | $1.65B |
Critical Care, Surgical Structural Heart were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| United States | $816.90M | $804.60M | $643.80M | $838.90M | $889.70M | $907.50M | $907.00M | $937.60M |
| Europe | $334.90M | $315.10M | $308.70M | $341.80M | $378.20M | $387.90M | $409.60M | $442.60M |
| Rest of World | $150.70M | $153.20M | $86.10M | $150.20M | $169.00M | $167.60M | $165.50M | $177.80M |
| Japan | $93.20M | $85.80M | $47.90M | $81.80M | $95.30M | $90.10M | $87.50M | $90.60M |
| Total | $1.37B | $1.35B | $1.39B | $1.41B | $1.53B | $1.55B | $1.57B | $1.65B |
Geographic Breakdown
| Segment | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|---|
| Europe | $290.80M | $331.10M | $336.20M | $322.30M | $344.90M | $367.80M | $335.60M | $319.80M |
| Rest Of World | $150.90M | $165.30M | $180.80M | $180.30M | $182.80M | $178.90M | $146.10M | $148.60M |
| Total | $1.35B | $1.46B | $1.53B | $1.48B | $1.27B | $1.33B | $1.37B | $1.35B |
Europe, Rest Of World were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Revenue at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's total revenue?
- Edwards Lifesciences (EW) reported total revenue of $1.65B in Q1 2026.
- How has Edwards Lifesciences's total revenue changed year-over-year?
- Edwards Lifesciences's total revenue increased by 16.7% year-over-year, from $1.41B to $1.65B.
- What is the long-term trend for Edwards Lifesciences's total revenue?
- Over 4 years (2021 to 2025), Edwards Lifesciences's total revenue has grown at a 3.8% compound annual growth rate (CAGR), from $5.23B to $6.07B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.